Blinatumomab Trial: 66 Percent of Patients Achieve Remission from Acute Lymphoblastic Leukemia

Lower toxicity than conventional chemo

Remission rates of elderly patients with acute lymphoblastic leukemia (ALL) on a novel immunotherapy regimen appear to at least equal those observed with conventional chemotherapy — with less toxicity.

Advertising Policy

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy

Results of the phase 2 trial of bispecific anti-CD19 antibody blinatumomab as induction and post-remission therapy were presented at the 2018 American Society of Hematology meeting in San Diego.

“Follow-up on the trial is still early, but the one-year estimated event-free and overall survival rates are encouraging,” says Anjali Advani, MD, Director of the Inpatient Leukemia Program at Cleveland Clinic Cancer Center. Dr. Advani was lead author of the study.

Immunotherapy-based regimens like this are likely to become the future standard of care for the elderly ALL population, which currently has a poor prognosis, she says.

The study

The antigen CD19 is expressed on most precursor B-cell ALLs. Previous studies have shown that the anti-CD19 antibody blinatumomab has been effective in relapsed/refractory ALL as well as minimal residual disease (MRD) ALL. That’s why Dr. Advani and a multicenter team through the National Clinical Trial Network evaluated the use of blinatumomab in patients (median age 75) with newly diagnosed Philadelphia chromosome negative B-lineage ALL.

Advertising Policy

Patients received blinatumomab for one to two cycles, until they attained a complete response (less than 5 percent marrow blasts with no evidence of extramedullary disease) with or without complete count recovery (absolute neutrophil count > 1000/uL, platelets > 100,000/uL). Once in remission, patients received three additional cycles of blinatumomab, followed by POMP (prednisone, vincristine, 6-mercaptopurine, methotrexate) therapy for 18 months.

Of the 29 patients treated, 19 (66 percent) had a complete response with or without complete count recovery. All but one of the 19 responded after only one cycle of blinatumomab. Of the 13 responders who had post-treatment MRD data, 12 (92 percent) achieved MRD negativity.

Kaplan Meier analysis estimates overall survival at six months to be 79 percent — 65 percent at one year. Disease-free survival at six months is estimated to be 68 percent — 56 percent at one year.

Hyperglycemia was the most common toxicity related to treatment, affecting four patients (14 percent). Toxicities affecting three patients (10 percent) were dyspnea, febrile neutropenia and hypertension. Two patients (7 percent) had lung infection.

Advertising Policy

There were no deaths in the first 28 days of the study treatment.

Next step: investigating drug combinations

“Novel therapeutic approaches are clearly needed for elderly patients with newly diagnosed ALL,” says Dr. Advani. “The outcomes of this treatment regimen appear promising.”

Longer follow-up is needed to determine duration of disease-free and overall survival.

Next steps will include investigating other treatments in combination with blinatumomab in the same population, notes Dr. Advani. One trial already in progress is studying the use of inotuzumab with blinatumomab.